JP2018502089A - Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ - Google Patents

Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ Download PDF

Info

Publication number
JP2018502089A
JP2018502089A JP2017533856A JP2017533856A JP2018502089A JP 2018502089 A JP2018502089 A JP 2018502089A JP 2017533856 A JP2017533856 A JP 2017533856A JP 2017533856 A JP2017533856 A JP 2017533856A JP 2018502089 A JP2018502089 A JP 2018502089A
Authority
JP
Japan
Prior art keywords
cancer
raf
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502089A5 (enExample
Inventor
ヴィヴィアーナ ボゾン，
ヴィヴィアーナ ボゾン，
キャサリン エム． ガルビン，
キャサリン エム． ガルビン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2018502089A publication Critical patent/JP2018502089A/ja
Publication of JP2018502089A5 publication Critical patent/JP2018502089A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017533856A 2014-12-23 2015-12-22 Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ Pending JP2018502089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
PCT/US2015/067459 WO2016106357A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2018502089A true JP2018502089A (ja) 2018-01-25
JP2018502089A5 JP2018502089A5 (enExample) 2019-02-07

Family

ID=56151529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533856A Pending JP2018502089A (ja) 2014-12-23 2015-12-22 Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ

Country Status (6)

Country Link
US (1) US20180263979A1 (enExample)
EP (1) EP3236948A4 (enExample)
JP (1) JP2018502089A (enExample)
CN (1) CN107205933A (enExample)
CA (1) CA2972076A1 (enExample)
WO (1) WO2016106357A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532065B1 (en) 2016-10-28 2024-04-24 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof
WO2018204226A1 (en) * 2017-05-03 2018-11-08 St. Jude Children's Research Hospital Compositions and methods for prevention and treatment of hearing loss
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. Solid dispersion of pan-raf kinase inhibitor
CN116004567A (zh) * 2022-12-07 2023-04-25 北京大学 极光激酶b基因k202突变及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510215A (ja) * 2006-11-16 2010-04-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂進行を阻害するための化合物
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
WO2013142491A1 (en) * 2012-03-20 2013-09-26 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2372782A1 (en) * 1999-05-11 2000-11-16 Wing Cheung Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
CN1835756A (zh) * 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
CN101056632B (zh) * 2004-11-09 2011-12-07 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
PL1896470T3 (pl) * 2005-05-16 2011-03-31 Irm Llc Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
SG11201610534UA (en) * 2014-06-16 2017-01-27 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510215A (ja) * 2006-11-16 2010-04-02 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂進行を阻害するための化合物
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
WO2013142491A1 (en) * 2012-03-20 2013-09-26 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2013144923A1 (en) * 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF CANCER, vol. Vol.50，Suppl.6, JPN6019042762, November 2014 (2014-11-01), pages 117 - 364, ISSN: 0004147662 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター

Also Published As

Publication number Publication date
CN107205933A (zh) 2017-09-26
EP3236948A4 (en) 2018-10-03
CA2972076A1 (en) 2016-06-30
WO2016106357A1 (en) 2016-06-30
EP3236948A1 (en) 2017-11-01
US20180263979A1 (en) 2018-09-20
WO2016106357A8 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
JP7265985B2 (ja) Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP2021156893A (ja) Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法
JP2013543008A (ja) Ｂｒａｆ阻害剤による治療方法
CN103097526B (zh) 赋予针对raf和mek抑制剂的抗性的mek1突变
JP2018502089A (ja) Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ
JP2024081710A (ja) ウイルス感染、炎症又は癌の処置におけるバイオマーカー及び使用
TW202039862A (zh) 受體酪氨酸激酶(kit)基因突變
JP5651125B2 (ja) Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
RS67265B1 (sr) Lečenje kancera koji ima gnaq ili gna11 genetske mutacije sa inhibitorima protein kinaze c
JP7734139B2 (ja) Ｎｒｇ１融合体を有するがんの治療のためのキナゾリンベースのチロシンキナーゼインヒビターの使用
GB2488028A (en) mTOR mutants as biomarkers for mTOR inhibitor treatment
US20200316067A1 (en) Combination of raf inhibitors and taxanes
MX2014006186A (es) Capacidad de respuesta a los inhibidores de la angiogenesis.
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
JP2018533627A (ja) 多発性骨髄腫を有する患者の識別方法、評価方法、及び治療方法
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors
WO2023211889A1 (en) Polymorphic compounds and uses thereof
ES2362115T3 (es) Composición farmacéutica para su uso en el tratamiento de individuos que presentan proteína kit mutante.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200623